.png)
GEMM™ for Human
We aim to apply GEMM technology to enhance gut health and immune responses, offering groundbreaking solutions for complex health challenges.
By 2030, an estimated 10 million people in the Western world alone will have IBD.² This figure does not even account for rapidly industrializing, highly populated countries like India and China, where IBD cases are only now beginning to surge - indicating a dramatic rise worldwide in the coming decades.
Inflammatory Bowel Disease
Current treatments for Inflammatory Bowel Disease (IBD) are not optimal, often resulting in unwanted side effects. The IBD treatment market is projected to reach $49.8 billion by 2034¹, highlighting a significant opportunity for innovative, more effective solutions. Furthermore, few treatments are available specifically for mild-to-moderate ulcerative colitis - a type of IBD. In a preclinical model, EcN::ttr showed superior efficacy over the frontline treatment for mild-to-moderate disease, suggesting EcN::ttr as a potential alternative.
At Melius, we are currently preparing a regulatory application in Australia to begin a Phase 1a/2a clinical trial.
_edited.png)